The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Health Agency Estimates 2015 Prescription Drug Spending Rose to $457 Billion

U.S. Health Agency Estimates 2015 Prescription Drug Spending Rose to $457 Billion

March 10, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—Spending on prescription drugs is projected to have risen to $457 billion in 2015 and will likely continue to grow as a percentage of overall healthcare spending, a U.S. government health agency said on Tuesday.

You Might Also Like
  • CMS Says U.S. Health Spending to Rise 5.5% Per Year over Next Decade
  • U.S. Health Spending Is Twice Other Countries’, with Worse Results
  • FDA Seeks Suspension of 4,402 Illegal Prescription Drug Websites

That is an increase of about 8% from 2014’s prescription drug spending, which is also an estimated figure, the government agency said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Prescription drug spending is estimated to have accounted for 16.7% of $2.729 trillion spent on healthcare last year, the U.S. Department of Health and Human Services‘ Office of the Assistant Secretary for Planning and Evaluation said in a report.

An estimated $328 billion was spent on retail drugs, the report said. It also estimated that another $128 billion was spent on non-retail drugs, such as cancer treatments that are administered in a physician’s office or hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The affordability of medicines has become an important issue for the 2016 presidential elections, and has become part of the campaign platforms of potential candidates Hillary Clinton and Donald Trump.

The agency forecast that total drug spending will grow to $535 billion in 2018 and represent about 16.8 percent of all healthcare spending.

The figures are based in part on National Health Expenditure Accounts (NHEA) estimates from the Centers for Medicaid and Medicare Services. These NHEA estimates represent a drug’s net price after adjusting for rebates and discounts. It estimated the non-retail drug spending portion as a ratio of retail spending.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The agency said that from 2010 to 2014, the spending increase was due to the following factors: 10% due to population growth, 30% due to the numbers of prescriptions per person increasing, 30% due to inflation and 30% due to price increases that were greater than inflation. Costs in the last category were boosted because of the changing composition of drugs to higher cost components, it said.

Filed Under: Drug Updates Tagged With: Centers for Medicare and Medicaid Services (CMS), cost, Prescription drugs, spending

You Might Also Like:
  • CMS Says U.S. Health Spending to Rise 5.5% Per Year over Next Decade
  • U.S. Health Spending Is Twice Other Countries’, with Worse Results
  • FDA Seeks Suspension of 4,402 Illegal Prescription Drug Websites
  • U.S. to Boost Drug Price Negotiation in Medicare Advantage Health Plans

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)